Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $4.11 Analyst target: $8.50 Upside: 106.81%
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral infections. The company is headquartered in Boston, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.